

Cover Story
FreeNews Analysis
By Matthew Bin Han Ong
Now that Joseph R. Biden Jr. is inaugurated and safely ensconced in the White House, cancer groups expect him to pick up where he left off as vice president four years ago—pursuing a sober and ambitious agenda for accelerating progress in cancer research.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Preparing to take care of each other in ways we never imagined
- 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- From the chairs of ECOG-ACRIN: A perspective on indirect costs
- On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”